Pozen, Inc. (POZN) Announces Licensing Deal with Desitin Pharmaceuticals GmbH for MT 400 Migraine Treatment in 29 European Countries
5/8/2012 10:40:34 AM
More...
|
Zogenix, Inc. and Desitin Pharmaceuticals GmbH Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom
1/6/2011 9:52:21 AM
More...
|
Zogenix, Inc. and Desitin Pharmaceuticals GmbH Announce First European Marketing Approval for SUMAVEL(R) DosePro(TM)
12/2/2010 11:27:57 AM
More...
|
Zogenix, Inc. and Desitin Pharmaceuticals GmbH Announce Filing for European Regulatory Approval of SUMAVEL(TM) DosePro(TM) - European Pivotal Trial Confirms Bioequivalence
10/28/2009 10:43:46 AM
More...
|
Zogenix, Inc. Licenses European Development and Commercial Rights for Sumatriptan DosePro(TM) to Desitin Pharmaceuticals GmbH
3/18/2008 10:32:32 AM
More...
|
Bourne Partners Advises Desitin Pharmaceuticals GmbH In Product Sale
4/19/2006 4:49:19 PM
More...
|